Clovis Plans Rucaparib Commercial Launch, After Abandoning Rociletinib

In light of FDA’s plan to issue a complete response letter, Clovis ends development of next-gen EGFR inhibitor rociletinib to save cash and refocuses on approval and launch of PARP inhibitor rucaparib for ovarian cancer.